The obesity drug producer has taken some hits throughout the past year, but it is beginning to punch back.Over the past several years, GLP-1 agonist weight-loss drugs have evolved from a celebrity trend to arguably the hottest growth opportunity in the pharmaceutical industry.Novo Nordisk (NVO +0.07%) jumped out to an early lead with the immense popularity of its Ozempic and Wegovy (semaglutide), used to treat type 2 diabetes and obesity. However, a shortage in 2022 spurred competition from compounding phar ...